CN111357979A - Health food composition for inhibiting obesity and bone loss caused by high fat and application thereof - Google Patents
Health food composition for inhibiting obesity and bone loss caused by high fat and application thereof Download PDFInfo
- Publication number
- CN111357979A CN111357979A CN201911361404.2A CN201911361404A CN111357979A CN 111357979 A CN111357979 A CN 111357979A CN 201911361404 A CN201911361404 A CN 201911361404A CN 111357979 A CN111357979 A CN 111357979A
- Authority
- CN
- China
- Prior art keywords
- health food
- high fat
- caused
- food composition
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 21
- 206010065687 Bone loss Diseases 0.000 title claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 9
- 208000008589 Obesity Diseases 0.000 title claims abstract description 8
- 235000020824 obesity Nutrition 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title claims description 14
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000009200 high fat diet Nutrition 0.000 claims abstract description 17
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 13
- 244000068988 Glycine max Species 0.000 claims abstract description 12
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 11
- 102000004877 Insulin Human genes 0.000 claims abstract description 9
- 108090001061 Insulin Proteins 0.000 claims abstract description 9
- 229940125396 insulin Drugs 0.000 claims abstract description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 8
- 210000000579 abdominal fat Anatomy 0.000 claims abstract description 8
- 239000008103 glucose Substances 0.000 claims abstract description 8
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 6
- 239000008280 blood Substances 0.000 claims abstract description 6
- 230000004584 weight gain Effects 0.000 claims abstract description 5
- 235000019786 weight gain Nutrition 0.000 claims abstract description 5
- 210000001596 intra-abdominal fat Anatomy 0.000 claims abstract description 4
- 241000700159 Rattus Species 0.000 claims description 26
- 210000002966 serum Anatomy 0.000 claims description 8
- 235000003687 soy isoflavones Nutrition 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000005484 gravity Effects 0.000 claims description 6
- 238000007410 oral glucose tolerance test Methods 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000007446 glucose tolerance test Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 235000005911 diet Nutrition 0.000 description 21
- 230000037213 diet Effects 0.000 description 17
- 229940071440 soy protein isolate Drugs 0.000 description 11
- 206010022489 Insulin Resistance Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 235000004213 low-fat Nutrition 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 150000002515 isoflavone derivatives Chemical class 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000002710 gonadal effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004067 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000014461 bone development Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000013597 soy food Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
- VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 102000002281 Adenylate kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102100027441 Nucleobindin-2 Human genes 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 1
- 235000019126 equol Nutrition 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 125000004402 polyphenol group Chemical group 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a health food for inhibiting obesity and bone loss caused by high fat and a product formula. The soybean isoflavone has effects in relieving weight gain caused by high fat diet, inhibiting visceral fat and abdominal fat weight increase caused by high fat diet, reducing blood glucose concentration and insulin concentration caused by high fat diet, and inhibiting bone loss caused by high fat. Can be used for preventing and treating bone mass reduction caused by high fat diet.
Description
Technical Field
The invention belongs to the field of health-care food, and particularly relates to health-care food for inhibiting obesity and bone loss caused by high-fat diet and a product dosage.
Background
Soy Isoflavone (SI) is a general name for a mixture of polyphenol structures, is a secondary metabolite formed in the growth process of soybeans, and is considered as a natural nutritional factor with various physiological activities. In general, soy isoflavones are powdery solids, yellowish white, bitter and astringent. Soy isoflavones are readily soluble in weak alkaline solutions, and free soy isoflavones are substantially insoluble in water. After the human body ingests the soybeans and the products thereof, the soybean isoflavones are mainly metabolized and absorbed in the intestinal tract and are converted into metabolic substances such as equol and the like to enter the blood. Research reports show that the soybean isoflavone has treatment and prevention effects on various diseases, including cardiovascular protection, anti-tumor, neuroprotection, liver protection, immunoregulation, diabetes treatment and osteoporosis prevention.
The development and maturation of the skeletal system in children is influenced by nutritional status, dietary factors, body composition and body weight. Myeloadiposis and systemic insulin resistance are common features of impaired bone mass/mass in patients with various diseases such as obesity, chronic alcohol abuse, diabetes and aging. Therefore, intraosseous insulin signaling may be critical to maintain bone marrow fat and bone mass at a well-balanced level. Recent studies in mice have shown that osteocalcin secretion, especially under the action of carboxylated osteocalcin, an active form of an osteoblast derived hormone, regulates insulin secretion, insulin sensitivity and energy expenditure in bone. Osteoblastic insulin receptor signaling is considered to be a positive factor in regulating acquired bone acquisition. In particular, recent clinical data show that overweight, insulin resistance and visceral obesity have a negative impact on adolescent bone mass. In this regard, Soy Protein Isolate (SPI) diets have been investigated as candidates for preventing early development of metabolic syndrome. Soy foods have been reported to have a variety of health benefits, including improved insulin sensitivity, weight control, and improved body composition. Soy foods have also been reported to prevent bone loss in adult human and animal models of osteoporosis. Activation of AMP kinase in adipose tissue and skeletal muscle was associated with improved lipid and glucose signaling in soy fed mice. The effects of soybean diet on bone are believed to be due to the potential estrogenic effects of high phytoestrogens (such as genistein and daidzein) with isoflavone structures similar to 17 estradiol. Dietary factors other than the isoflavone fraction, including unidentified peptides present in serum after feeding soybeans, may have an effect on bone and other organ systems. We have recently demonstrated the positive effect of the soybean diet on systemic insulin resistance. Data from studies indicate that free fatty acids (NEFA), bone insulin resistance, osteoblast differentiation and decreased activity appear to be the major mediators of High Fat (HF) induced bone development and model injury. We have further found that diets containing SPI prevent bone development and bone model damage during early development, which is associated with reduced bone fat and increased bone insulin sensitivity.
With the increasing aging of the Chinese population, the osteoporosis problem has become a serious public health problem. Osteoporosis is mainly caused by bone formation less than bone resorption, imbalance of bone metabolism and decreased bone mass. The research shows that the soybean isoflavone can form a compound with an estrogen receptor of osteoblast, promote the bone secretion and ensure that the bone absorption and the bone formation are in a dynamic balance state. And simultaneously inhibits the proliferation of bone marrow B lymphocytes, thereby preventing the occurrence of osteoporosis. The clinical use of isoflavones (synthetic isoflavones) to reduce menopausal bone loss is strong evidence that isoflavones can prevent and treat osteoporosis.
Disclosure of Invention
The invention provides a health food composition capable of inhibiting obesity and bone acquisition disorder caused by high-fat diet and application thereof.
The technical scheme of the invention is as follows:
a health food composition for inhibiting obesity and bone acquisition disorder caused by high fat diet comprises adjuvants and effective component, wherein the effective component is soybean isoflavone.
Preferably, the product can relieve weight gain caused by high fat diet.
Preferably, the product can inhibit increase of visceral fat specific gravity and abdominal fat specific gravity of rat caused by high fat diet.
Preferably, the product can reduce the increase of blood glucose concentration caused by high fat diet.
Preferably, the product can reduce serum insulin levels after an OGTT.
Preferably, the product inhibits bone loss caused by high fat.
Compared with the prior art, the invention has the beneficial effects that:
the soybean isoflavone is used as an effective component of the health food, and the prepared health food can relieve weight gain caused by high fat diet, inhibit the increase of visceral fat specific gravity and abdominal fat specific gravity of rats, reduce the serum insulin concentration after OGTT and inhibit bone loss caused by high fat.
Drawings
FIG. 1 shows the body weight change curves of rats in four different diet groups.
Figure 2 statistical plots of gonadal fat and abdominal fat in four different dietary groups.
FIG. 3 changes in serum glucose and insulin concentrations for four different dietary groups.
Figure 4 effect of four different diets on high fat induced bone acquisition disorders in rats.
Detailed Description
Male Sprague-Dawley rats were purchased from Harlan Industries (indianapolis, usa) and arrived at the laboratory on postnatal day 20 (PND), with PDN24 randomized into 4 groups (n ═ 10). Rats were fed with 4 feeds, a standard low-fat AIN-93G diet (LF-Cas) was formulated with casein (Cas) as the sole protein source (LF; 5%); adopting LF diet prepared by AIN-93G formula, substituting Cas with SPI to prepare LF-SPI diet; the HF/High-cholesterol diet contained 18.8MJ/g energy, 195g/kg casein, 483g/kg carbohydrate, 210g/kg anhydrous milk fat, 5g/kg cholesterol and 50g/kg cellulose fiber (HF-Cas); the HF-SPI panel was identical to the prior HF-Cas diet panel except Cas was replaced by SPI and supplemental amino acids. Thus, there are 2 LF diets, 1 Cas (LF-Cas), 1 SPI (LF-SPI), 2 HF diets, 1 Cas (HF-Cas), and 1 SPI (HF-SPI). Rats were fed four diets from PND24 to PND68, respectively. The HF-SPI group was free to receive food and water, while the other three groups were fed in pairs based on total calories. Since the rats fed in pairs eat all the food, the food intake of four groups of rats was strictly controlled. Rats were housed in an animal facility approved by the animal care laboratory at the Acken Children hospital institute, maintained at constant humidity, and illuminated at a temperature of 22 ℃ from 06:00 to 18: 00. Physical activity between animals is considered similar. All animal experiments were approved by the animal care and use committee of the medical science agency of the university of akkern. The rats were monitored for body weight for 2 weeks. Rats were subjected to a standard Oral Glucose Tolerance Test (OGTT) and tail vein bleeds 7d prior to sacrifice. After the experiment was completed, pentobarbital sodium (100mg/kg) was injected for anesthesia, the rats were sacrificed, and the rat legs and serum were collected. Gonads and abdominal adipose tissue were also taken and their weights were recorded. Rat serum insulin concentrations were determined by ELISA (EZRMI-13K) (Linco Research, St. Charles, MO, USA). The glucose concentration in serum was determined by glucose oxidase method (IR 070; Synermed, Westfeld, USA).
Example 1
Rats were fed Low Fat (LF) or High Fat (HF) feed with casein (Cas) or Soy Protein Isolate (SPI) addition. Rats were fed group by group. Rats fed HF-Cas weighed 465.0 + -12.1 g vs.395.5 + -19.7 g (P ═ 0.026) more than rats fed LF-Cas. The rats in the LF-SPI fed group had the lowest body weight (p <0.05), while the rats in the HF-SPI fed group had body weights similar to those in the LF-Cas group (fig. 1), indicating that the SPI-containing diet had a remitting effect on high fat diet-induced weight gain.
Example 2
When the local fat mass is expressed as a percentage of body weight, the abdominal fat pad (1.61 + -0.21%) and gonadal fat pad (1.39 + -0.11%) of the rats in the HF-Cas fed group were greater than those in the LF-Cas fed group (0.85 + -0.08% and 0.81 + -0.0%, P <0.05), respectively. Gonadal fat pads were smaller in the LF-SPI diet group (p <0.05), but similar in abdominal fat pads compared to the rats in the LF-Cas diet group (fig. 2). Thus, SPI was able to prevent HF-induced increase in body fat in rats.
Example 3
We performed OGTT and tail blood insulin concentration measurements at PND 61. In the HF-Cas group of animals, blood glucose and insulin concentrations were higher at 60, 90 and 150 minutes post stimulation with glucose than in the other groups (p < 0.05). The LF-SPI group showed the highest insulin sensitivity, and the LF-Cas group showed similar results to the HF-SPI group (FIG. 3). The results show that the HF-SPI group can significantly prevent hyperglycemia compared to the HF-Cas group (fig. 3).
Example 4
The tibial micro-CT analysis showed the phenotype as shown in figure 4. Wherein the rat bone volume, trabecular number and trabecular thickness of the HF-Cas group are all reduced compared with the animals of the LF-Cas group. But these parameters are highest in the LF-SPI group. However, the HF-Cas group had a greater trabecular spacing in rats compared to the other groups. The results demonstrate that low bone mass is associated with a high fat diet and that soy isoflavones can significantly improve this trend.
Claims (7)
1. A health food composition for inhibiting obesity and bone acquisition disorder caused by high fat diet comprises adjuvants and effective component, wherein the effective component is soybean isoflavone.
2. Use of the health food composition as set forth in claim 1 for preparing a health food for alleviating weight gain caused by high fat diet.
3. Use of the health food composition as set forth in claim 2 for preparing a health food which can reduce the specific gravity of visceral fat and the specific gravity of abdominal fat of rats caused by high fat diet.
4. Use of the health food composition as set forth in claim 2 for the preparation of a health food for lowering the increase of blood glucose level caused by a high-fat diet.
5. Use of the health food composition as set forth in claim 2 for the preparation of a health food which can lower the serum insulin concentration after the glucose tolerance test (OGTT).
6. Use of the health food composition as set forth in claim 2 for preparing a health food which can inhibit bone loss caused by high fat.
7. Use of the health food composition as defined in claim 2 for the preparation of health food wherein the dosage of said health food is 15g of soy isoflavone powder per day, and the dosage of children is halved.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911361404.2A CN111357979A (en) | 2019-12-26 | 2019-12-26 | Health food composition for inhibiting obesity and bone loss caused by high fat and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911361404.2A CN111357979A (en) | 2019-12-26 | 2019-12-26 | Health food composition for inhibiting obesity and bone loss caused by high fat and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111357979A true CN111357979A (en) | 2020-07-03 |
Family
ID=71198216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911361404.2A Pending CN111357979A (en) | 2019-12-26 | 2019-12-26 | Health food composition for inhibiting obesity and bone loss caused by high fat and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111357979A (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1383426A (en) * | 2000-07-07 | 2002-12-04 | 尼基摩株式会社 | Obesity inhibitory materials |
| CN1416411A (en) * | 2000-02-01 | 2003-05-07 | 斯特维亚私人有限公司 | Substance for use in dietary supplementation or for prepn. of medicament for treating non-insulin dependent diabetes mellitus, Hypertension and/or metabolic syndrome |
| TW200518762A (en) * | 2003-12-04 | 2005-06-16 | Souriree Biotech Pharmaceutical Co Ltd | Composition for relieving menopause disturbance, and preventing osteoporosis, and its application |
| CN1660125A (en) * | 2004-12-16 | 2005-08-31 | 南开大学 | New capability and application of soybean isoflavone for enhancing and improving memory |
| CN101181069A (en) * | 2007-11-30 | 2008-05-21 | 天津科技大学 | Complex nutrition albumen powder for preventing women's osteosporosis after menopause |
| CN101534817A (en) * | 2006-10-31 | 2009-09-16 | 株式会社太平洋 | Use for treating obesity and diabetes |
| CN102802428A (en) * | 2009-06-12 | 2012-11-28 | 卡勒纳斯公司 | Copepod oil composition, formulations comprising the oil composition, and the use thereof to reduce accumulation of visceral fat, improve glucose tolerance, and prevent or treat obesity related diseases and disorders |
| CN104887738A (en) * | 2015-05-17 | 2015-09-09 | 郑毅男 | Preparation method and application of vegetable soybean extract |
| CN107949394A (en) * | 2015-08-19 | 2018-04-20 | 韩国生命工学研究院 | It is used to prevent or treats metabolic syndrome or for oxidation resistant composition comprising black soya bean leaf extract and from its separated flavonol glycosides is as active component |
| CN108991515A (en) * | 2018-08-07 | 2018-12-14 | 成都大学附属医院 | A kind of high fat diet formula |
| CN110583579A (en) * | 2019-09-25 | 2019-12-20 | 南开大学 | Function and application of voltage-gated proton channel Hv1 in treating obesity |
-
2019
- 2019-12-26 CN CN201911361404.2A patent/CN111357979A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416411A (en) * | 2000-02-01 | 2003-05-07 | 斯特维亚私人有限公司 | Substance for use in dietary supplementation or for prepn. of medicament for treating non-insulin dependent diabetes mellitus, Hypertension and/or metabolic syndrome |
| CN1383426A (en) * | 2000-07-07 | 2002-12-04 | 尼基摩株式会社 | Obesity inhibitory materials |
| TW200518762A (en) * | 2003-12-04 | 2005-06-16 | Souriree Biotech Pharmaceutical Co Ltd | Composition for relieving menopause disturbance, and preventing osteoporosis, and its application |
| CN1660125A (en) * | 2004-12-16 | 2005-08-31 | 南开大学 | New capability and application of soybean isoflavone for enhancing and improving memory |
| CN101534817A (en) * | 2006-10-31 | 2009-09-16 | 株式会社太平洋 | Use for treating obesity and diabetes |
| CN101181069A (en) * | 2007-11-30 | 2008-05-21 | 天津科技大学 | Complex nutrition albumen powder for preventing women's osteosporosis after menopause |
| CN102802428A (en) * | 2009-06-12 | 2012-11-28 | 卡勒纳斯公司 | Copepod oil composition, formulations comprising the oil composition, and the use thereof to reduce accumulation of visceral fat, improve glucose tolerance, and prevent or treat obesity related diseases and disorders |
| CN104887738A (en) * | 2015-05-17 | 2015-09-09 | 郑毅男 | Preparation method and application of vegetable soybean extract |
| CN107949394A (en) * | 2015-08-19 | 2018-04-20 | 韩国生命工学研究院 | It is used to prevent or treats metabolic syndrome or for oxidation resistant composition comprising black soya bean leaf extract and from its separated flavonol glycosides is as active component |
| CN108991515A (en) * | 2018-08-07 | 2018-12-14 | 成都大学附属医院 | A kind of high fat diet formula |
| CN110583579A (en) * | 2019-09-25 | 2019-12-20 | 南开大学 | Function and application of voltage-gated proton channel Hv1 in treating obesity |
Non-Patent Citations (1)
| Title |
|---|
| 陈世伟，等: "大豆异黄酮对膳食诱导胰岛素抵抗大鼠脂联素基因表达的影响", 《卫生研究》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tew et al. | A diet high in wheat fiber decreases the bioavailability of soybean isoflavones in a single meal fed to women | |
| Geinoz et al. | Relationship between bone mineral density and dietary intakes in the elderly | |
| EP0656786B1 (en) | Use of isoflavone phyto-oestrogen extracts of soy or clover | |
| US6197832B1 (en) | Composition for reducing serum cholesterol levels | |
| JP2009511522A (en) | New use of nutraceutical composition | |
| Fayed | Health benefits of some physiologically active ingredients and their suitability as yoghurt fortifiers | |
| CN103889432B (en) | Muscle mass dose | |
| CN111569052A (en) | Composition for increasing bone mineral density of climacteric women and health product and application thereof | |
| Shiguemoto et al. | Isoflavone-supplemented soy yoghurt associated with resistive physical exercise increase bone mineral density of ovariectomized rats | |
| WO2002004437A1 (en) | Obesity inhibitory materials | |
| AU2006347122B2 (en) | Antiobesity composition containing component originating in the bark of tree belonging to the genus Acacia | |
| KR101491595B1 (en) | Pharmaceutical composition for promoting osteogenesis containing axial-equatorial aryl-oriented furofuran-type lignan, and pharmaceutical preparation, functional food product, and health food product comprising composition | |
| Batool et al. | Exploring Flaxseed's potential in enhancing bone health: Unveiling osteo-protective properties | |
| CN111357979A (en) | Health food composition for inhibiting obesity and bone loss caused by high fat and application thereof | |
| US20040097429A1 (en) | Method for the reduction of the mammalian appetite | |
| EP3494973B1 (en) | Compositions comprising 7-o-genistein phosphate for use in the treatment of primary osteoporosis | |
| US20050123633A1 (en) | Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon | |
| Myung-Ye et al. | Effects of cheonggukjang containing arrowroot isoflavones on bone metabolism in ovariectomized rats | |
| TW200812569A (en) | Bone density increasing agent | |
| WO2021065661A1 (en) | Composition for suppression of decrease in muscle mass, prevention of decrease therein, maintenance thereof, recovery thereof or increase therein | |
| WO2013174812A1 (en) | Fructus ligustri lucidi for bones in young subjects | |
| KR102620793B1 (en) | Composition for preventing, ameliorating or treating woman menopausal symptom comprising mixture of fermented soybean and fermented lettuce as effective component | |
| WO2001087315A1 (en) | Treatment or prevention of metabolic bone disorder | |
| JPH078803B2 (en) | Hypocholesterolemia treatment | |
| US20080161385A1 (en) | Composition Inhibiting Sex Hormone-Binding Globulin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200703 |
|
| RJ01 | Rejection of invention patent application after publication |